Limit size lipid nanoparticles and related methods
US-2016214103-A1 · Jul 28, 2016 · US
Methods for manufacturing an adjuvant
US12016919B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12016919-B2 |
| Application number | US-201816616999-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 23, 2018 |
| Priority date | May 30, 2017 |
| Publication date | Jun 25, 2024 |
| Grant date | Jun 25, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A solution comprising a solvent and 100-170 mg/ml phosphatidylcholine lipid, wherein the solvent comprises 70-90% v/v ethanol and 10-30% v/v isopropyl alcohol. 2. The solution according to claim 1 , comprising 100-160 mg/ml phosphatidylcholine. 3. The solution according to claim 2 , comprising 120-140 mg/ml phosphatidylcholine. 4. The solution according to claim 1 , further comprising 20-50 mg/ml sterol. 5. The solution according to claim 4 , comprising 30-40 mg/ml of sterol. 6. The solution according to claim 4 , wherein the ratio of phosphatidylcholine to sterol is 3:1 to 5:1. 7. The solution according to claim 4 , wherein the sterol is cholesterol. 8. The solution according to claim 1 , further comprising a Toll-like receptor 4 (TLR4) agonist. 9. The solution according to claim 8 , wherein the TLR4 agonist is a lipopolysaccharide. 10. The solution according to claim 9 , wherein the lipopolysaccharide is 3-de-O-acylated monophosphoryl lipid A (3D-MPL). 11. The solution according to claim 8 , wherein the TLR4 agonist is present at a concentration of 4-12 mg/ml. 12. The solution according to claim 1 , wherein the solvent comprises 75-85% v/v ethanol. 13. The solution according to claim 1 , wherein the solvent comprises 15-25% v/v isopropanol. 14. The solution according to claim 1 , wherein the solvent comprises 78-82% v/v ethanol, and 18-22% v/v isopropyl alcohol. 15. The solution according to claim 1 , wherein the phosphatidylcholine lipid contains saturated unbranched acyl chains having 12-20 carbon atoms. 16. The solution according to claim 15 , wherein the lipid is dioleoyl phosphatidylcholine (DOPC). 17. A solution which consists essentially of a solvent and 100-160 mg/ml DOPC, 30-40 mg/ml cholesterol, 4-10 mg/ml TLR4 agonist, and wherein the solvent comprises 70-90% v/v ethanol and 10-30% v/v isopropyl alcohol. 18. The solution according to claim 17 wherein the TLR4 agonist is a lipopolysaccharide. 19. The solution according to claim 18 , wherein the lipopolysaccharide is 3D-MPL.
Assignees
Inventors
Classifications
Mixers with a converging cross-section · CPC title
Mixing of ingredients for pharmaceutical or medical compositions · CPC title
Microemulsions · CPC title
Mixing chamber · CPC title
Methods of emulsifying · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12016919B2 cover?
- The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.
- Who is the assignee on this patent?
- Glaxosmithkline Biologicals Sa, Glaxosmithkline Biologicals Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K39/39. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).